Legal & General Group Plc Makes New $1.58 Million Investment in Amphastar Pharmaceuticals, Inc. $AMPH

Legal & General Group Plc acquired a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 78,281 shares of the company’s stock, valued at approximately $1,580,000. Legal & General Group Plc owned 0.18% of Amphastar Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. ProShare Advisors LLC increased its stake in shares of Amphastar Pharmaceuticals by 5.3% in the 4th quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock worth $243,000 after acquiring an additional 457 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Amphastar Pharmaceuticals by 2.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 19,397 shares of the company’s stock valued at $478,000 after purchasing an additional 459 shares in the last quarter. Advisory Research Inc. increased its stake in shares of Amphastar Pharmaceuticals by 3.8% during the third quarter. Advisory Research Inc. now owns 15,468 shares of the company’s stock valued at $412,000 after purchasing an additional 570 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Amphastar Pharmaceuticals by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after purchasing an additional 613 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in shares of Amphastar Pharmaceuticals by 6.2% in the 4th quarter. Janney Montgomery Scott LLC now owns 14,230 shares of the company’s stock worth $381,000 after purchasing an additional 825 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Amphastar Pharmaceuticals

In related news, CFO William Peters sold 8,180 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $22.48, for a total value of $183,886.40. Following the sale, the chief financial officer owned 172,846 shares in the company, valued at approximately $3,885,578.08. This trade represents a 4.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Rong Zhou sold 3,187 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $23.63, for a total transaction of $75,308.81. Following the completion of the sale, the executive vice president directly owned 169,203 shares of the company’s stock, valued at approximately $3,998,266.89. This trade represents a 1.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 19,340 shares of company stock worth $421,047 over the last three months. 29.60% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $23.18 on Monday. The stock has a market capitalization of $986.08 million, a P/E ratio of 13.72, a P/E/G ratio of 4.47 and a beta of 0.92. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.40 and a quick ratio of 1.71. Amphastar Pharmaceuticals, Inc. has a 1-year low of $16.65 and a 1-year high of $29.78. The business has a fifty day moving average price of $20.51 and a 200-day moving average price of $20.55.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.62 by $0.29. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%.The company had revenue of $183.90 million during the quarter, compared to the consensus estimate of $179.92 million. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AMPH. Bank of America reiterated an “underperform” rating and set a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Wells Fargo & Company lifted their price target on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Finally, Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Reduce” and a consensus target price of $22.50.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.